Phase II Study of Gefitinib in Patients With Relapsed or Persistent Ovarian or Primary Peritoneal Carcinoma and Evaluation of Epidermal Growth Factor Receptor Mutations and Immunohistochemical Expression: A Gynecologic Oncology Group Study

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-05-0462
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Phase II Evaluation of Dasatinib in the Treatment of Recurrent or Persistent Epithelial Ovarian or Primary Peritoneal Carcinoma: A Gynecologic Oncology Group Study

Gynecologic Oncology
GynecologyOncologyObstetrics
2012English

A Phase II Evaluation of Lapatinib in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma: A Gynecologic Oncology Group Study

Gynecologic Oncology
GynecologyOncologyObstetrics
2012English

Phase II Study of Bevacizumab and Pemetrexed for Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Gynecologic Oncology
GynecologyOncologyObstetrics
2013English

A Phase II Evaluation of Nintedanib (BIBF-1120) in the Treatment of Recurrent or Persistent Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study

Gynecologic Oncology
GynecologyOncologyObstetrics
2014English

A Phase 2 Study of Alisertib (MLN8237) in Recurrent or Persistent Uterine Leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group Study 0231D

Gynecologic Oncology
GynecologyOncologyObstetrics
2017English

Phase II Trial of Nab-Paclitaxel in the Treatment of Recurrent or Persistent Advanced Cervix Cancer: A Gynecologic Oncology Group Study

Gynecologic Oncology
GynecologyOncologyObstetrics
2012English

Cetuximab and Platinum-Based Chemoradio- Or Chemotherapy of Patients With Epidermal Growth Factor Receptor Expressing Adenoid Cystic Carcinoma: A Phase II Trial

British Journal of Cancer
Cancer ResearchOncology
2013English

Phase II Study of Intermediate-Dose Cytarabine in Patients With Relapsed or Refractory Ewing Sarcoma: A Report From the Children's Oncology Group

Pediatric Blood and Cancer
OncologyChild HealthHematologyPerinatologyMedicinePediatrics
2009English

A Phase II Evaluation of Selumetinib (AZD6244, ARRY-142886), a Selective MEK-1/2 Inhibitor in the Treatment of Recurrent or Persistent Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study

Gynecologic Oncology
GynecologyOncologyObstetrics
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy